Related Experiment Video
Updated: Jul 15, 2026

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Adiponectin protects against the development of systolic dysfunction following myocardial infarction
Rei Shibata1, Yasuhiro Izumiya, Kaori Sato
1Molecular Cardiology/Whitaker Cardiovascular Institute, Boston University School of Medicine, 715 Albany Street, W611, Boston, MA 02118, USA.
Insights
Adiponectin protects the heart after myocardial infarction by reducing cardiac remodeling and improving function. This study shows adiponectin deficiency worsens heart failure, while supplementation improves outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Molecular Biology
Background:
- Obesity is linked to heart failure with left ventricular (LV) dysfunction.
- Adiponectin, an adipocyte hormone, is reduced in obesity.
- The role of adiponectin in cardiac remodeling post-myocardial infarction (MI) is unclear.
Purpose of the Study:
- To investigate the function of adiponectin in cardiac remodeling following myocardial infarction.
- To assess the effects of adiponectin deficiency and supplementation on cardiac structure and function.
Main Methods:
- Myocardial infarction induced in adiponectin-deficient (APN-KO) and wild-type (WT) mice via LAD ligation.
- Adenoviral vectors used for systemic adiponectin or beta-galactosidase delivery.
- Cardiac function assessed by echocardiography and Millar catheterization; histological analysis for capillary density, apoptosis, and fibrosis.
Main Results:
- APN-KO mice exhibited worsened LV dilation, hypertrophy, and contractile dysfunction post-MI compared to WT mice.
- APN-KO mice showed increased myocyte apoptosis, interstitial fibrosis, and reduced capillary density.
- Adiponectin administration in WT mice improved LV function, reduced hypertrophy, apoptosis, and fibrosis, and increased capillary density.
Conclusions:
- Adiponectin plays a protective role against systolic dysfunction after myocardial infarction.
- Adiponectin mitigates cardiac remodeling by suppressing hypertrophy, fibrosis, and cell loss.
- Targeting adiponectin may be a therapeutic strategy for post-myocardial infarction recovery.
Abstract:
There is an association between obesity and heart failure associated with LV dysfunction. Adiponectin is an adipocyte-derived hormone that is downregulated in obesity. Here, we examined the role of adiponectin in cardiac remodeling after myocardial infarction with loss- and gain-of-function genetic manipulations in an experimental model. Myocardial infarction was created in adiponectin-deficient (APN-KO) and wild-type (WT) mice by the permanent ligation of the left anterior descending (LAD) artery. For some experiments, adenoviral vectors expressing adiponectin or beta-galactosidase were delivered systemically. Cardiac structure and function were assessed by echocardiographic and Millar catheter measurements. Myocardial capillary density was assessed by staining with anti-CD31 antibody. Myocyte apoptotic activity was determined by TUNEL-staining. Myocardial interstitial fibrosis was evaluated by Masson's trichrome staining. APN-KO mice showed exacerbated left ventricular (LV) dilation, myocyte hypertrophy and contractile dysfunction compared with WT mice at 4 weeks after LAD ligation. Impaired LV function in APN-KO mice was coupled to myocyte hypertrophy, increased apoptotic activity and interstitial fibrosis in the remote zone, and reduced capillary density in the infarct border zone. No difference in infarct size was observed between WT and APN-KO mice. Administration of adenovirus-mediated adiponectin in WT mice resulted in decreased LV dilatation and improved LV function that was associated with increased capillary density in the infarct border zone and decreased myocyte hypertrophy, diminished myocardial apoptosis and decreased interstitial fibrosis in the remote zone. These data suggest that adiponectin protects against the development of systolic dysfunction after myocardial infarction through its abilities to suppress cardiac hypertrophy and interstitial fibrosis, and protect against myocyte and capillary loss.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Heart Failure II: Pathophysiology
